Effect of vitramin D in asthma
Phase 3
- Conditions
- Asthma.Asthma
- Registration Number
- IRCT20190721044288N1
- Lead Sponsor
- Birjand University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
moderate to severe asthma
treated with inhaled corticosteroid (ICS)
vitamin D deficiency
No systemic disease
No diabetes
No infectious disease
No liver disease
No heart disease
No kidney disease
Exclusion Criteria
patient expired
patient who do not use his drug
add new systemic disease
change of treatment
Patients taking antioxidant drugs
Use of any medication that affects the mitochondrial system and antioxidant storage
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum levels of antioxidants in the blood serum of patients. Timepoint: Measurement of serum antioxidant levels at the beginning of the study and 3 months after starting vitamin D intake. Method of measurement: Use of thiobarbituric acid method.;Serum levels of interleukin 10 in the blood serum of patients. Timepoint: Measurement of serum interleukin level 10 at the beginning of the study and 3 months after starting vitamin D intake. Method of measurement: Using the commercial kit by ELISA method.
- Secondary Outcome Measures
Name Time Method